接受乳腺癌辅助内分泌疗法治疗的妇女的副作用
L M Rademaker1, R Gal2, A M May1
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Breast (Edinburgh, Scotland)
|February 20, 2025
概括
许多乳腺癌患者因血管运动和肌肉骨症状等副作用而提前停止内分泌治疗. 解决这些副作用对于改善治疗坚持和降低死亡风险至关重要.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 辅助内分泌疗法对于乳腺癌管理至关重要.
- 过早停止这种治疗与较差的患者结局和增加的死亡率有关.
- 了解停止治疗的原因,特别是副作用,对于改善药物坚持至关重要.
研究的目的:
- 为了确定接受乳腺癌辅助内分泌治疗的妇女中副作用的患病率.
- 调查经历过的副作用与内分泌治疗的过早中止之间的关联.
- 探索前期化疗治疗对副作用经验和治疗坚持的影响.
主要方法:
- 在荷兰的UMBRELLA队列中,对456名女性进行了横截面调查.
- 参与者是目前或以前使用辅助内分泌疗法的人.
- 收集的数据包括经历过的副作用,停止治疗的原因和治疗史.
主要成果:
- 92.7%的目前内分泌治疗使用者报告了副作用的高患病率,血管运动和肌肉骨症状是最常见的.
- 副作用是早期停药的主要原因,由88.1%的前用户引用.
- 以前接受化疗的妇女报告了更多的副作用 (97.2%),但不太可能过早停止内分泌疗法 (18.6%),与没有先前接受化疗的妇女相比 (28.6%).
结论:
- 在辅助内分泌治疗的妇女中,副作用的普遍性很高,并且是早期停止治疗的主要驱动因素.
- 虽然化疗史与增加的副作用负担相关,但矛盾的是,它与更低的内分泌治疗中止率有关.
- 管理副作用的策略对于改善辅助内分泌治疗的坚持和减轻乳腺癌死亡率至关重要.
相关概念视频
Disorders of the Female Reproductive System
298
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
298
Menopause
117
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
117
Hormonal Regulation of the Menstrual Cycle
261
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
261
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
172
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
172
Oogenesis
63.3K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.3K
Hormonal Control of the Ovarian Cycle
386
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
386


